Ainos, Inc. — Filing identity and reporting period
The supplied filing is Amarillo Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2015; it does not identify Ainos, Inc. as the registrant. The company describes itself as a biopharmaceutical research and development business focused on low-dose oral interferon and other health-related opportunities. It reported no product revenue. Following its November 2014 emergence from Chapter 11, the company applied fresh-start accounting, so 2015 Successor results are not directly comparable with 2014 Predecessor results.
Financial highlights
- Revenue and margins: No revenue or cost of revenue in the three or six months ended June 30, 2015 or the comparable 2014 periods. Gross profit was zero.
- Quarter ended June 30: SG&A was $102,103, down from $186,203 in 2014; operating loss was $102,103 versus $186,203; net loss was $102,849 versus $186,887. Interest expense was $746.
- Six months ended June 30: SG&A was $213,921 versus $345,948; R&D was zero versus $15,270; operating loss was $213,921 versus $361,218; net loss was $214,938 versus $361,948. Interest expense was $1,017. Per-share loss was $0.01 for both six-month periods, though weighted-average shares differed substantially.
- Cash flow: Six-month operating cash use was $207,426, investing cash use was $11,066, and financing cash flow was zero. Cash declined by $218,492 to $100,064 from $318,556 at the start of 2015. The comparable 2014 period used $183,690 in operations and ended with $1,490 cash.
- Balance sheet and liquidity: At June 30, cash was $100,064 and total assets were $238,685. Current liabilities were $371,865 versus current assets of $151,277, a working-capital deficit of $220,588. Total liabilities were $484,365; related-party notes payable totaled $384,555, comprising $272,055 current and $112,500 long-term. Stockholders’ deficit was $245,680.
- Capitalization: 20,144,810 common shares were outstanding at June 30 and August 10, 2015. No shares were issued in the first six months of 2015.
Changes, outlook, and risks
- Management attributed lower quarterly and six-month losses mainly to reduced salaries, professional fees, and bankruptcy-reorganization expenses. R&D remained suspended.
- The company exited Chapter 11 in January 2015. Its reorganization discharged substantial debt; management reported debt falling from $4.8 million before reorganization to $452,277 at December 31, 2014. June 30 liabilities were higher, including related-party notes.
- Management estimated post-reorganization financing needs of $1.0 million to $1.6 million. Yang indicated willingness to assist but made no commitment and was not obligated to provide funds. The company warned that inability to obtain acceptable financing could force it to cease operations; the filing states substantial doubt about its ability to continue as a going concern.
- Management did not expect meaningful revenue from commercialization efforts before the last quarter of 2016 or later, and did not expect significant sales or royalty revenue in the next several years. No specific revenue or earnings guidance was provided.
- Key risks include the discontinued sole source of human interferon, the time and cost of finding a replacement and obtaining testing and regulatory approval, and patent expiry: two patents were due to expire in less than seven months and three in four to seven years. The ACM supplier’s price increase also made the oral-health product less attractive to manufacture and sell.
- Most assets reportedly secure Yang-related debt. Yang held approximately 80% of the reorganized company. A July 10, 2015 shareholder meeting changed governance and voting provisions and elected a new board; the filing expected Yang to distribute 11,453,334 shares to its constituent members.
- Management said disclosure controls were effective and reported no significant changes in internal controls. It reported no known pending legal proceedings, no defaults upon senior securities, and no stock sales during the period.
Investor verification priorities
- Confirm the issuer identity: the provided filing is for Amarillo Biosciences, Inc., not Ainos, Inc.
- Reconcile the filing’s inconsistent six-month loss figures: the financial statements report net loss of $214,938, while a risk-factor passage states $241,938. The statements report operating loss of $213,921; MD&A contains an apparent erroneous description of the year-over-year change as an “increase.”
- Assess near-term cash needs, actual monthly cash burn, and whether Yang or another source will provide the estimated $1.0 million to $1.6 million of financing.
- Verify the status of interferon supply, development and regulatory plans, patent expirations, and the prospects and timing for any commercial revenue.
- Review the July 2015 ownership distribution and governance changes, including subsequent disclosures on new major shareholders.